{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-009179","form_type":"8-K","ticker":"LPCN","cik":"0001535955","company_name":"Lipocine Inc.","filed_at":"2025-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.682761+00:00","generated_at":"2026-05-22T04:14:11.508471+00:00","sec_items":["8.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Lipocine Q1 net loss $1.9M; starts Phase 3 for PPD drug LPCN 1154","bullets":["Net loss $1.9M ($0.35 diluted share) vs net income $3.5M ($0.66) in Q1 2024.","Cash and equivalents $19.7M at March 31, 2025, down from $21.6M at Dec 31, 2024.","Initiated outpatient Phase 3 study of LPCN 1154 (oral brexanolone) for postpartum depression; first patient dosing expected Q2 2025.","Entered TLANDO license agreement for Brazil with Aché; exploring partnerships for LPCN 1154 and LPCN 2401.","Plans proof-of-concept study for LPCN 2401 as adjunct to GLP-1 therapies, targeting elderly patients."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-009179","json":"https://secwatch.observer/filing/0001641172-25-009179.json","markdown":"https://secwatch.observer/filing/0001641172-25-009179.md","text":"https://secwatch.observer/filing/0001641172-25-009179.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1535955/000164117225009179/0001641172-25-009179-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1535955/000164117225009179/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T04:14:11.508471+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}